investors.rapt.com Open in urlscan Pro
2a02:26f0:480:d::210:f15f  Public Scan

Form analysis
1 forms found in the DOM

GET https://www.rapt.com/

<form role="search" method="get" class="search-form" action="https://www.rapt.com/">
  <input type="text" name="s">
</form>

Text Content

Skip to main navigation
 * About
   * Who We Are
   * Leadership Team
   * Board of Directors
   * Clinical And Scientific Advisors
   * Contact
 * Science
   * Immune Continuum
   * CCR4 in Cancer
   * CCR4 in Inflammation
   * GCN2
   * Publications
 * Pipeline
   * Snapshot
   * FLX475
   * RPT193
   * GCN2i
   * HPK1
   * Discovery Programs
 * Clinical Trials
   * Overview
 * Investors & Media
   * Corporate Profile
   * Press Releases
   * Events and Presentations
   * Stock Information
   * Corporate Governance
   * SEC Filings
   * Email Alerts
   * Investor Contact
   * Investor FAQs
 * Careers
   * Culture
   * Benefits
   * Open Positions
 * 


INVESTOR RELATIONS


CORPORATE PROFILE

RAPT Therapeutics is a clinical stage immunology-based biopharmaceutical company
focused on discovering, developing and commercializing oral small molecule
therapies for patients with significant unmet needs in inflammatory diseases and
cancer. Utilizing our proprietary drug discovery and development engine, we
develop highly selective small molecules that are designed to modulate the
critical immune responses underlying these diseases. Since our founding, we have
discovered and advanced to clinical development two drug candidates, each
targeting CCR4. In a randomized, placebo-controlled Phase 1b study in patients
with atopic dermatitis, our lead inflammation drug candidate, RPT193,
demonstrated clinically meaningful improvement in several exploratory endpoints.
Our lead oncology drug candidate, FLX475, is in development for a range of
tumors. We are also pursuing a range of other targets, including HPK1, that are
in earlier stages of discovery and development.

NASDAQ: RAPT
$9.09 -0.1 (-0.55%)

Data Provided by Refinitiv. Minimum 15 minutes delayed.


Press Releases
March 7, 2024
RAPT Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
March 5, 2024
RAPT Therapeutics Announces Multiple Late-Breaking Presentations at the Upcoming
American Association for Cancer Research (AACR) Annual Meeting


SEE ALL NEWS
Upcoming Events
There are no events scheduled at this time.


See all events
Latest Presentation
January 2024 Corporate Presentation


See all presentations
Investor Inquiries
investors@rapt.com
Shareholder tools
Print page
RSS feeds
Share page
E-mail alerts
 * Facebook1
 * LinkedIn
 * Twitter

Close
Contact Us
+1.650.489.9000
inquiries@rapt.com

 * Home
 * About
 * Science
 * Pipeline
 * Investors
 * Careers

 * Terms of Use
 * Privacy Policy

RAPT Therapeutics, Inc.
561 Eccles Avenue
South San Francisco, CA 94080

RAPT Therapeutics, formerly known as FLX Bio.

© 2024 RAPT Therapeutics , Inc. All right reserved.